FTC and states sue telehealth firm Hims & Hers over health-data sharing

Worried that a telehealth site shared sensitive health data with advertisers or signed you up for recurring prescription charges without clear consent? This guide breaks down what the FTC and state partners allege against Hims & Hers and what the case could mean for privacy promises, tracking tools, and subscription billing rules. ReferU.AI can help you find an attorney with experience in telehealth privacy and negative option subscription disputes.

FTC and states sue telehealth firm Hims & Hers over health-data sharing
Type
Child
Status
Approved
Title (YouTube)
Images Failed (Social)
Do not index
Publish Date (TikTok)
Videos Post IDs (Social)
Hashtags (Social)
Caption
Caption X
Cover
ftc-hims-hers-health-data-sharing-telehealth-privacy-lawsuit.png
OG Image
ftc-hims-hers-health-data-sharing-telehealth-privacy-lawsuit.png
Alt Image Text
Flat vector illustration of FTC and states suing Hims & Hers over health-data sharing, showing a telehealth app, consumer health data flowing to ad networks, and legal privacy enforcement in a telehealth privacy lawsuit.
Images
Videos
Publish Date (Social)
Scheduled (Social)
Images Posted (Social)
Videos Posted (Social)
Featured
Created time
Jul 30, 2026 10:05 PM
Sub-item
Authors
CTA Practice Area (Social)
TikTok Failed (Social)
Videos Post Links (Social)
TikTok Post Links (Social)
Images Post IDs (Social)
YT Post ID
Video Pending Manual (Social)
TikTok Posted (Social)
TikTok Post IDs (Social)
Video Cover (Social)
Images Post Links (Social)
First Comment (Social)
Videos Failed (Social)
YT Embedded
Images Delete (Social)
Videos Delete (Social)
Carousel Video URL (Social)
Federal regulators escalated scrutiny of consumer telehealth on July 29, 2026, when the Federal Trade Commission, joined by Utah and Los Angeles County on behalf of California, filed a federal complaint against Hims & Hers in the Northern District of California. The lawsuit alleges the San Francisco-based telehealth company deceptively shared sensitive health information with advertising platforms and used recurring subscription practices that left consumers enrolled and billed without clear consent.
In the FTC’s announcement of the privacy and subscription case, regulators say Hims transmitted consumer health information to Meta, Snap, and other third parties despite privacy promises, and also failed to clearly disclose when prescription charges would begin and recur. The case, filed as Case No. 3:26-cv-07871 in the Northern District of California action, may become one of the more closely watched enforcement tests for digital health companies using ad-tech tools and subscription billing.

What Regulators Allege

According to the 48-page complaint filed on July 29, 2026, the government claims Hims misled “hundreds of thousands” of consumers by charging them for prescription subscriptions without express informed consent and by making cancellation difficult. The complaint says consumers were led to believe they were submitting information for review and possible consultation, while in many cases they were allegedly charged and enrolled in recurring plans shortly after submitting an intake form.
The filing also centers on alleged privacy representations. Regulators point to Hims’ “100% online, private, and secure” messaging and argue those statements conveyed that sensitive health information would remain confined to medical providers rather than be disclosed to advertisers. The complaint alleges the company then shared data through customer-list uploads and tracking technologies.
More specifically, the government alleges Hims shared event-level website “Events” data and customer information with advertising platforms, including Meta and Snap. The complaint also describes the use of Meta Pixel and Conversions API tools, and alleges Hims used pixels from additional ad platforms such as Microsoft and Google.
On the subscription side, the FTC’s press release describing the billing allegations says Hims did not clearly disclose that many consumers would be charged for prescriptions almost immediately after submitting intake forms. Regulators also allege that users were placed into recurring subscription plans shortly after intake, and that refill timing and cancellation pathways were obscured.

Why This Case Matters Beyond One Company

This lawsuit lands at a moment when telehealth, direct-to-consumer prescribing, and digital advertising have become tightly intertwined. Many platforms collect detailed health-related responses before a user ever speaks with a clinician, and those systems often rely on analytics, pixels, APIs, and marketing integrations built for e-commerce rather than medical confidentiality.
That tension is what makes this case important. In general terms, the government appears to be arguing that a telehealth intake funnel cannot operate like a standard online retail checkout when the information involved concerns erectile dysfunction, hair loss, mental health, weight management, or other highly personal conditions. The legal theory is not just about a privacy policy sentence in isolation; it is about whether the overall user experience created a misleading impression about confidentiality, consent, billing, and cancellation. The FTC says those alleged practices violate Section 5 of the FTC Act and ROSCA, while California and Utah also assert state-law claims.
The FTC has brought prior privacy cases involving health-related apps and data sharing, and the agency maintains a broader privacy and security enforcement program aimed at companies that allegedly break privacy promises or misuse sensitive consumer information. What makes the Hims matter stand out is the combination of health-data sharing allegations and negative-option subscription allegations in one direct-to-consumer medical platform case.

The Legal Framework Behind The Claims

The federal claims rely on two familiar consumer-protection tools.
First, Section 5 of the FTC Act bars unfair or deceptive acts or practices. In privacy cases, the FTC often uses Section 5 when a company says one thing about personal information and allegedly does another. Here, the complaint frames Hims’ representations about privacy, provider access, and consent as potentially deceptive if consumers were given a materially different experience.
Second, the complaint invokes the Restore Online Shoppers’ Confidence Act, often called ROSCA. That law is frequently used in cases involving online negative-option features, recurring charges, and cancellation design. The government’s theory appears to focus on whether Hims clearly disclosed all material subscription terms, obtained informed consent before charging consumers, and offered a simple way to stop recurring billing.
California’s claims under the Unfair Competition Law and False Advertising Law, along with Utah’s claim under the Utah Consumer Sales Practices Act, raise the stakes further. Multi-jurisdiction enforcement often signals that regulators view the conduct as part of a broader consumer-protection priority rather than a one-off dispute.

What Telehealth Companies May Be Watching Closely

For digital health businesses, this case may become a roadmap for what regulators see as risky design choices.
One likely pressure point is the gap between medical privacy branding and marketing-tech implementation. A platform may present itself as clinically private while still using ad tools that capture highly revealing consumer behavior. Regulators appear increasingly willing to look past generic privacy disclosures and examine the actual technical flows behind the scenes.
Another likely pressure point is the conversion of a medical intake form into a billing event. In a typical retail setting, auto-enrollment and pre-checked assumptions already carry legal risk. In a healthcare-adjacent setting, that risk may look even more significant when the purchase follows disclosure of intimate medical concerns and when the user reasonably expects a clinician conversation before a charge.
A third issue is cancellation friction. The FTC’s allegations about hidden cancellation steps and delayed visibility of the cancel option fit into a broader enforcement pattern around online subscription traps. For telehealth companies, that can be especially sensitive where recurring shipments involve prescription products, refill timing, and continuing charges tied to health treatment.

What Consumers And Businesses May Take From The Filing

For consumers, this lawsuit is a reminder that online healthcare platforms can involve more than a doctor-patient interaction. They may also involve checkout design, recurring billing systems, audience-matching tools, and tracking technologies operating in the background. When a user enters symptoms, treatment interests, or medical history, questions often arise about where that information actually goes and who can use it.
For companies, the filing suggests regulators are paying close attention to whether “privacy” and “easy cancellation” are functioning promises or merely marketing language. Businesses operating in telehealth, wellness, fertility, mental health, weight loss, or prescription delivery may be watching this case for signals about consent flows, ad-tech governance, data minimization, and subscription disclosures.
For investors and industry observers, the matter may also say something larger about enforcement priorities in 2026: regulators appear increasingly interested in how platforms monetize sensitive health journeys, not just whether a company posted a privacy policy somewhere on its website.

What Affected Parties Might Consider

People who used a telehealth platform and later discovered recurring charges, disputed refills, or suspected sharing of sensitive health information may want to consider preserving screenshots, billing records, intake emails, cancellation attempts, and copies of any privacy disclosures they saw at the time. In situations involving prescription auto-renewals or health-data concerns, an attorney might help determine whether federal or state consumer-protection laws are potentially relevant and whether individual claims, arbitration issues, or class-action developments are worth monitoring.
Companies facing questions about similar practices may also be reviewing how intake flows, pixels, customer-list uploads, refill notices, and cancellation paths interact. In general terms, legal exposure in this area often turns on details that look minor in product design but significant in litigation.
Visit ReferU.AI to get matched with an attorney who has demonstrable experience in cases like yours — for free.